Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.